Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

REACHING “UNDRUGGABLE” TARGETS

Most medicines today fall into one of two categories: small molecules or biologics. Both types have inherent limitations. Macrocycles occupy a middle ground between the two, giving them the potential to combine the best attributes of each while overcoming their shortcomings.

Small molecule medications are well-structured, stable, can often be taken orally, and are relatively easy and inexpensive to make. However, they can usually only address disease targets that have appropriate pockets on their surface into which small molecules can bind. These binding pockets provide several points of contact between the small molecule drug and the target protein, allowing the drug to modify the function of the protein. But small molecule medications cannot easily disrupt protein-to-protein interactions implicated in many diseases because these protein-to-protein interactions often do not have suitable deep pockets for small molecule medications to bind.

Biologics, such as antibodies, on the other hand, are significantly larger and can provide exquisite selectivity and potency against a target, including protein-protein interactions.

However, they are unable to cross cell membranes and so cannot be absorbed if swallowed and must be injected. Further, their inability to cross membranes means that they cannot access protein-protein interactions that are inside cells. Intracellular protein-protein interactions are central to many disease processes, including many cancers and inflammatory diseases.

Thus, a vast number of therapeutic targets are beyond the reach of these two conventional drug classes. Scientists call these hard-to-reach human proteins “undruggable targets.”